Membranous Nephropathy. Glomerular Diseases
Conditions
Interventions
Intervention 1: standard treatment regimen + placebo (400 mg, three times/day, for 6 months). Intervention 2: standard treatment regimen + pentoxifylline (400 mg, three times/day, for 6 months).
Placebo
Treatment - Drugs
standard treatment regimen + placebo (400 mg, three times/day, for 6 months)
standard treatment regimen + pentoxifylline (400 mg, three times/day, for 6 months)
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
14 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: New cases with biopsy proven Membranous Nephropathy, Initial Random urine protein (mg/dl) > 2 g/day based on 24-hr urine collection Exclusion Criteria: Pregnancy, Breast feeding, Diabetes Mellitus, History of allergy to Pentoxifylline or any derivatives of methyl xanthenes, Cerebral hemorrhage or Retinal hemorrhage within the past 6 months prior to signing the informed consent form, Congestive heart failure (NYHA functional class III or IV), Uncontrolled hypertension (SBP > 200 mmHg and/or DBP > 110 mmHg), history of unstable angina, myocardial infarction, cerebrovascular accidents, Stroke, Obstructive uropathy, Cirrhosis, Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST > 5 times the upper limit of the normal range, or > 3 times concomitant with signs and symptoms of hepatic failure
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary protein excretion. Timepoint: 2 and 6 months after study initiation. Method of measurement: Measurement of Urinary Protein Excretion based on 24-hr urine collection. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glomerular Filtration Rate (GFR). Timepoint: 2 and 6 months after study initiation. Method of measurement: GFR will be calculated by Cockcroft-Gault formula. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed